

























































published: 03 November 2014
doi: 10.3389/fimmu.2014.00557
PI3K signaling in B cell andT cell biology
Klaus Okkenhaug1*, MartinTurner 1 and Michael R. Gold 2
1 Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK
2 Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada
*Correspondence: klaus.okkenhaug@babraham.ac.uk
Edited and reviewed by:
Ellis L. Reinherz, Dana-Farber Cancer Institute, USA
Keywords: PI3K/AKT/mTOR, PI3K pathway inhibitors,T cell, B cell, signal transduction
The drug Idelalisib is the first PI3K inhibitor to be approved by
the FDA for clinical use. It is therefore timely to take stock of our
current understanding of the role of PI3Ks in the immune system.
The phosphoinositide 3-kinases (PI3Ks) control many key func-
tions in immune cells (1). PI3Ks phosphorylate PtdIns(4,5)P2 to
yield PtdIns(3,4,5)P3, which acts as a second messenger signaling
molecule that controls the activation of Akt and other proteins
with PH domains. Initially, PI3K inhibitors such as Wortman-
nin, LY294002, and Rapamycin were used to establish a central
role for PI3K pathway in immune cells. More recent progress in
understanding the role of this pathway in cells of the immune
system has been made through the generation of wide range of
gene-targeted mouse models as well as with the development
of highly selective small molecule inhibitors, culminating in the
FDA approval of the PI3Kδ inhibitor Idelalisib in 2014. Together,
lab experiments, preclinical, and clinical trials have revealed how
PI3Ks control B cell and T cell development, T helper cell differ-
entiation, regulatory T cell (Treg) development and function, B
cell and T cell trafficking, immunoglobulin class switching, and
much more.
The class I PI3Ks are heterodimers composed of a catalytic
subunit and a regulatory subunit. The p110α, p110β, and p110δ
catalytic subunits form heterodimers with either of the p85α,p55α,
p50α, p85β, or p55γ regulatory subunits, each of which contains
SH2 domains that are engaged by tyrosine phosphorylated pro-
teins. By contrast, the p110γ catalytic subunit forms heterodimers
with either the p84 or p101 regulatory subunits that are recruited
to the Gβγ subunits released by G-protein coupled receptors. The
respective heterodimers are often referred to as PI3Kα, PI3Kβ,
PI3Kδ, or PI3Kγ, respectively. Progress has been made in under-
standing the often non-redundant roles of each of these PI3K
isoforms in immunity (2). The majority of these efforts have been
directed at PI3Kδ and PI3Kγ, which are highly expressed in cells
of the immune system.
mTOR inhibitors such as rapamycin are already established as
among the most commonly used drugs to prevent transplant rejec-
tion and are increasingly also evaluated for the use in cancer (3).
Most recently, the PI3Kδ-selective inhibitor Idelalisib (CAL-101)
has received FDA approval for the treatment of chronic lympho-
cyte leukemia and indolent non-Hodgkin’s lymphoma following
on from successful clinical trials showing dramatic improvements
in progress-free survival (4, 5). Many other PI3K inhibitors are
going through clinical trials with the aim to treat cancers, and
inflammatory and autoimmune diseases.
This eBook contains 11 chapters that cover different roles of the
PI3K and mTOR pathways, primarily in B cells and T cells. Limon
and Fruman review the role of PI3Ks in B cell development and
activation and also consider how the related Akt, Foxo, and mTOR
pathways affect B cell biology (6). Marshall and colleagues present
a complementary view, focusing on the different mechanisms of
activation of PI3K in B cells, and the roles of the different phos-
phatases as well as individual role for additional PIP3 effectors
such as Bam32, Tapp1, and Tapp2 (7). Puri and Gold pick up on
this theme and further explore the clinical utility of blocking PI3K
activity in B cells, both in the context of autoimmune diseases, but
also by summarizing the early clinical trials that led to accelerated
approval of Idelalisib for the treatment of B cell lymphomas (8).
Bhatt and Damania consider the roles of PI3K and mTOR in the
transformation of B cells by Kaposi sarcoma viruses and how PI3K
and/or mTOR inhibitors should be considered for the treatment
of virally induced lymphomas (9).
Lewings and colleagues consider how PI3K signaling strength
affects T cell differentiation events. Their data show that high lev-
els of PI3K signaling can antagonize the differentiation of Treg
in favor of the differentiation of effector T cells (10). Okkenhaug
and colleagues present a somewhat different perspective, reviewing
evidence that low PI3K activity is also detrimental to Treg func-
tion and attempt to reconcile some of the different conclusions
regarding the role of PI3K in Treg function (11). Newton and
Turka consider the role of the PIP3 phosphatase Pten in T cells
and how unrestrained PI3K signaling can lead to T cell transfor-
mation (12). They further discuss the differential roles of Pten on
PI3K signaling and genome stability. Gamper and Powell discuss
data that challenge the common assumption that PI3K and mTOR
lie on a common pathway, by providing a detailed discussion of
similarities but importantly also key differences in the phenotypes
observed when either PI3K or mTOR is inhibited in CD4 T cells
(13). Similarly, Finlay discusses recent data showing that the PI3K
is in fact dispensable for mTOR activation in CD8 T cells and that
a Pdk1–mTOR axis regulates T cell metabolism independently of
PI3K and Akt (14).
These studies indicate that we need to start considering other
signaling pathways regulated by PI3K. Venigalla and Turner sum-
marize recent evidence suggesting a key role for PI3K, often in
concert with p38, in regulating mRNA stability and translation
(15). Some of these effects may also be mediated by mTOR.
Drugs against PI3K have become a clinical reality. However, not
all PI3K isoforms can be targeted as specifically as Idelalisib inhibits
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PI3Kδ. Blunt and Ward summarized the progress in developing
PI3K inhibitors, with particular focus on Idelalisib, but then go
on to summarize the roles of the PIP3 5-phosphatases SHIP1 and
SHIP2 (16). Moreover, they review the development of allosteric
drugs that activate SHIP as an alternative strategy to inhibit PI3K
signaling in immune cells.
Altogether, these reviews summarize the remarkable progress
in our understanding of how PI3Ks regulate many facets of the
adaptive immune response, but also help highlight many unre-
solved and even controversial areas of research. We are grateful
for the considerable efforts that the authors have made to help us
compile this ebook for Frontiers in Immunology.
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